15:07:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 Årsstämma 2024
2024-03-13 Bokslutskommuniké 2023
2023-11-22 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Årsstämma 2022
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2022-02-03 18:19:02
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE

Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company")  on 14 January 2022, regarding a proposed fully
underwritten rights issue (the "Rights Issue"), which is subject to the approval
by the extraordinary general meeting of the Company to be held at 10:00 (CET) on
4 February 2022.

The Company's board of directors has today, on 3 February 2022, based on a
recommendation from Carnegie AS and DNB Markets, a part of DNB Bank ASA (acting
as "Managers" in the Rights Issue), determined the following proposed (i)
subscription price, (ii) number of new shares and (iii) share capital increase
pertaining to the Rights Issue:

· The subscription price is proposed to be NOK 7.0 per new share offered in
the Rights Issue (the "Offer Shares"), representing a discount of 30% to the
theoretical ex rights price (TERP) of the Company's shares based on the volume
-weighted average price (VWAP) of the Company's shares on Euronext Expand in the
three days' period from 1 February 2022 to and including 3 February 2022, of NOK
13.939